Clinical Trial Update: HR Versus RFA for HCC in Patients With PHT [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HR versus RFA for hepatocellular carcinoma in patients with portal hypertension; status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Neoplasms

Snippet

Sponsor: Guangxi Medical University | Conditions: Carcinoma, Hepatocellular, Liver Neoplasms | Phase 3 | Status: UNKNOWN